12 results about "Cytotoxicity testing" patented technology

This invention discloses a method and system for cell viability detection using dual-channel differential dynamic adhesion impedance analysis. The system utilizes a microfluidic chip integrating detection and reference channels to synchronously apply fluid disturbances to both channels, inducing a dynamic process of "adhesion → detachment → re-adhesion" in cells. During this process, the differential impedance curve (after background subtraction) is acquired in real time, and six dynamic feature parameters, including the amplitude and rate of decrease and recovery, are extracted. A ridge regression algorithm is used to construct a cell viability prediction model, and the six dynamic feature parameters are input into the model to obtain cell viability values. This invention effectively eliminates environmental and fluid common-mode noise through differential structure and achieves label-free, in-situ, highly sensitive measurement of cell viability using impedance analysis. It has advantages such as accurate results, good stability, and high automation, and is suitable for fields such as cytotoxicity testing and drug screening.

The invention discloses application of neochlorogenic acid in preparation of a medicine for preventing and / or treating hand-foot-and-mouth disease caused by A16 type coxsackie virus (CVA16) infection, and belongs to the technical field of biological medicine. Researches prove that the neochlorogenic acid has the effect of resisting CVA16 infection on HEK293T cells and H4 cells, after the two cells treated by the neochlorogenic acid are infected by the CVA16, the viral genome RNA abundance is obviously reduced, and the cell lesion death condition is obviously relieved; meanwhile, a cytotoxicity test shows that the neochlorogenic acid has no obvious cytotoxicity to HEK293T cells and only has weak cytotoxicity to H4 cells. Therefore, in a reasonable dosage range, the neochlorogenic acid, which is a low-toxicity natural small molecule compound, can be used for preparing the anti-CVA16 medicine for preventing and / or treating the hand-foot-and-mouth disease caused by CVA16 infection.

The invention belongs to the technical field of nano material preparation and application, and discloses a method for liquid-phase stripping of iron oxychloride by cysteine and application. The method comprises the following steps: firstly, preparing blocky iron oxychloride through partial thermal decomposition of ferric chloride hexahydrate; and adding L-cysteine into the iron oxychloride solution, and carrying out ultrasonic treatment at 20-40kHz and 10-40 DEG C for 0.5-6 hours to finally prepare the cysteine-iron oxychloride nano material. The average size of the material is 20-200nm, and the material is strip-shaped, is rich in ferrous iron and oxygen vacancies, and has excellent peroxidase-like activity and Fenton reaction activity. The method is green, simple, convenient and low in cost. The prepared nano material can efficiently catalyze and generate active oxygen species such as hydroxyl free radicals, effectively kills drug-resistant escherichia coli and staphylococcus aureus through multiple mechanisms such as initiation of bacterial lipid peroxidation, DNA degradation and protein leakage consumption, shows good biocompatibility in a cytotoxicity test, and can be used for preparing a drug-resistant nano material. Wide application prospects are realized in the field of antibacterial preparations.

The invention provides low-toxicity and low-sensitization fluororubber watchband glue as well as a preparation method and application thereof, and belongs to the technical field of rubber materials. According to the technical scheme of the invention, the raw fluororubber is polymerized by adopting the surfactant containing no fluorine element, and meanwhile, the reinforcing filler system is optimized, so that the skin sensitization and stimulation risks are remarkably reduced. The fluororubber watchband adhesive prepared by the preparation method disclosed by the invention shows excellent biological safety in a cytotoxicity test. The invention provides a novel environment-friendly material solution with safety and reliability for the field of wearable equipment, particularly watchband products in long-term contact with human skin, and has definite market application prospect and popularization value.

The invention relates to the field of deep processing of cornus officinalis kernels, in particular to a cornus officinalis kernel extract with high biocompatibility as well as a preparation method and application of the cornus officinalis kernel extract. The method comprises the following steps: crushing dried cornus officinalis kernels, and performing reflux extraction with an absolute ethyl alcohol solution at 80 DEG C for 3 times, 2 hours each time; and combining the extracting solutions, filtering, carrying out vacuum concentration on the suction filtrate by using a rotary evaporator, and freeze-drying to obtain the dogwood kernel extract. The dogwood kernel component has a test concentration of 0.125-4 mg / mL, and has an obvious free radical scavenging effect, and the scavenging rate is enhanced along with the increase of the concentration and can reach 75% at most; in a CCK-8 method cytotoxicity test, the cell survival rate of the culture medium PC12 containing the cornus officinalis kernel component is 100% or above; the research proves that the dogwood kernel extract has better antioxidant activity, neuroprotective effect and cell safety, and provides a basis for further development and utilization of dogwood kernels.

The present invention relates to a lipid-lowering small-molecule peptide and its use. The lipid-lowering small-molecule peptide has the sequence LPSYSNAPYI and effectively inhibits pancreatic lipase activity and preadipocyte differentiation. This lipid-lowering small-molecule peptide can reduce levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol, while promoting an increase in high-density lipoprotein cholesterol. Furthermore, this lipid-lowering small-molecule peptide has been shown to be highly safe through cytotoxicity testing.

This invention provides naphthoquinone compounds targeting the novel coronavirus and their pharmaceutical uses. In vitro activity assays show that the compounds disclosed in this invention can inhibit the main protease (Mpro) activity of the SARS-CoV-2 novel coronavirus. In vitro activity assays show that some compounds, at a concentration of 1 μM, exhibit an enzyme inhibition rate of over 90%, significantly superior to the positive control drug shikonin, and can effectively reduce the replication capacity of wild-type and various mutant strains of the novel coronavirus in the host. In vitro cytotoxicity assays show that the compounds disclosed in this patent have significantly lower toxicity to normal host cells (HSF cells) than the positive control drug shikonin, indicating promising application prospects as drug candidates against COVID-19 infection.

The invention provides an acylhydrazone-Mn complex as well as a preparation method and application thereof. The structural formula of the acylhydrazone-Mn complex is shown in the specification, or in the structural formula, R is a substituent group. According to the invention, 4-diphenylaminobenzoylhydrazone reacts with MnCl2, the acylhydrazone-Mn complex is obtained by utilizing easy formation, strong coordination ability, diverse applications and biological activity of acylhydrazone compounds and utilizing N, O atoms and a plurality of metal ions to form complexes with different structures and properties, and some complexes have the characteristics of anti-tumor and antibacterial activity. A cytotoxicity test, an in-vitro proliferation inhibition activity experiment and an antibacterial experiment show that the synthesized Mn complex not only has a relatively good inhibition effect on tumor cells, but also has relatively low toxicity on normal cells; in addition, the proliferation of P.micro can be effectively inhibited.

The application discloses a lysosome-targeting near-infrared fluorescent probe and a preparation method and application thereof in carboxylesterase detection, wherein the structure of the lysosome-targeting near-infrared fluorescent probe is shown in the following formula: The lysosome-targeting near-infrared fluorescent probe of the application shows a rapid response (response time is 40 seconds) to carboxylesterase (CE) in an in-vitro experiment. Cell toxicity test shows that the probe has low biological toxicity, and confocal fluorescence microscopic imaging experiment shows that the fluorescent probe has good light stability in HeLa cells and can effectively target lysosomes (localization coefficient is 0.86), and is suitable for CE near-infrared region fluorescence imaging and detection in lysosomes of living cells.

The present invention discloses the use of KN-93 in the preparation of drugs for inhibiting porcine delta coronavirus, and relates to the technical fields of cell biology and virology. The present invention comprehensively utilizes technologies such as cell biology and virology, and finds that the calmodulin-dependent protein kinase II inhibitor KN-93 has the effect of inhibiting porcine delta coronavirus infection in vitro. First, KN-93 is subjected to cytotoxicity testing to determine the maximum safe concentration of the drug, and then fluorescent quantitative PCR (RT-qPCR), TCID 50 The in vitro inhibition of PDCoV infection by 10 μmol / L KN-93 was determined by ELISA and IFA, and it was found to significantly inhibit porcine deltacoronavirus. Therefore, KN-93 can be used to prepare drugs that inhibit porcine deltacoronavirus.

The application discloses a medical use of a 7-aminocephalosporanic acid derivative for resisting new coronavirus infection, and a structural formula of the compound is as follows: wherein R1 is hydrogen, (Z)-2-(2-amino-4-thiazolyl)-2-(carboxymethoxy imine) acetyl or (R)-2-amino-2-(4-hydroxyphenyl) acetyl; and R2 is acetyloxymethyl, ethenyl or 1-propenyl. In vitro activity test results show that the compound disclosed by the application can inhibit the binding of the spike protein of the new coronavirus SARS-CoV-2 to the receptor on the host cell membrane, and can effectively reduce the infectivity of the wild strain and various mutant strains of the new coronavirus. In vitro cytotoxicity test results show that the compound does not show cytotoxicity, and has been clinically used as an anti-inflammatory drug. The old drug is used for new use, and the compound is used for an anti-new coronavirus infection drug, thereby providing a new idea for new coronavirus epidemic prevention and control, and having a good application prospect.

The application discloses a kind of detection tyrosinase dual-channel near-infrared ratio fluorescent probe and its preparation method and purposes, wherein the structure of detection tyrosinase dual-channel near-infrared ratio fluorescent probe is as follows: the dual-channel near-infrared ratio fluorescent probe LZD of the application shows good selectivity and sensitive dual-channel fluorescence signal to tyrosinase.Cytotoxicity test shows that the ratio probe has good biocompatibility, and confocal fluorescence microscopic imaging experiment shows that the ratio probe has good light stability to HepG2 cells, can respond to tyrosinase through dual-channel fluorescence, and can carry out confocal fluorescence imaging to extracellular and endogenous tyrosinase of cell.